5 Stocks Pushing The Health Care Sector Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 33 points (-0.2%) at 14,002 as of Wednesday, Feb. 20, 2013, 11:50 AM ET. The NYSE advances/declines ratio sits at 1,057 issues advancing vs. 1,779 declining with 154 unchanged.

The Health Care sector currently sits down 0.1% versus the S&P 500, which is down 0.5%. Top gainers within the sector include Pharmacyclics Incorporated ( PCYC), up 2.4%, Express Scripts ( ESRX), up 1.9%, Alexion Pharmaceuticals ( ALXN), up 1.4%, Amgen ( AMGN), up 1.1% and Teva Pharmaceutical Industries ( TEVA), up 0.7%. On the negative front, top decliners within the sector include Life Technologies ( LIFE), down 7.4%, Thermo Fisher Scientific ( TMO), down 2.5%, Medtronic ( MDT), down 2.2%, UnitedHealth Group ( UNH), down 1.8% and Cigna ( CI), down 1.0%.

TheStreet Ratings group would like to highlight 5 stocks pushing the sector higher today:

5. Novo Nordisk A/S ( NVO) is one of the companies pushing the Health Care sector higher today. As of noon trading, Novo Nordisk A/S is up $2.42 (1.4%) to $175.39 on light volume Thus far, 99,328 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 298,900 shares. The stock has ranged in price between $174.86-$176.02 after having opened the day at $175.23 as compared to the previous trading day's close of $172.97.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products in Denmark and internationally. The company operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $96.0 billion and is part of the drugs industry. The company has a P/E ratio of 4.0, below the S&P 500 P/E ratio of 17.7. Shares are up 5.0% year to date as of the close of trading on Tuesday. Currently there are 2 analysts that rate Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Novo Nordisk A/S Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you liked this article you might like

Novo Nordisk Shares Leap Higher After Solid Earnings and Full-Year Sales Upgrade

Nevada Senate Passes Bill to Force Diabetes Drug Manufacturers to Disclose Pricing Practices

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Daily Earnings Round-Up

5 Things You Must Know Before the Market Opens Wednesday